<DOC>
	<DOCNO>NCT01471210</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , pharmacokinetics immunoregulatory activity urelumab ( BMS-663513 ) cancer subject advance and/or metastatic tumor relapsed/refractory B-Cell Non-Hodgkin 's Lymphoma</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics , Immunoregulatory Study Urelumab ( BMS-663513 ) Subjects With Advanced and/or Metastatic Solid Tumors Relapsed/Refractory B-cell Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . 1 . Signed Written Informed Consent The sign informed consent form 2 . Target Population Subjects advance and/or metastatic solid tumor BNHL either refractory relapsed standard therapy , standard therapy exist measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 criterion Life expectancy 12 week great Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 1 Adequate organ marrow function For certain subject , willing able provide pre posttreatment fresh tumor biopsy 3 . Age Reproductive Status Women childbearing potential ( WOCBP ) men must use acceptable method contraception avoid pregnancy throughout study least 4 week prior initiation dosing , least 60 day last dose investigational product manner risk pregnancy minimize WOCBP must negative serum urine pregnancy test [ minimum sensitivity 25 UI/L equivalent unit human chorionic gonadotrophin ( HCG ) ] within 24 hour prior start investigational product Women must breastfeed 1 . Target Disease Exceptions Subjects know suspect brain metastasis unless previously treat without evidence progression Subjects history prior malignancy active within previous 2 year except locally curable cancer apparently cure Subjects hepatocellular carcinoma 2 . Medical History Concurrent Diseases Any active autoimmune disease document history autoimmune disease , history syndrome require systemic steroid immunosuppressive medication , except subject vitiligo , psoriasis inactive within past 2 year , resolve childhood asthma/atopy , thyroid disease control replacement therapy without need immunosuppression Known suspect human immunodeficiency virus ( HIV ) hepatitis A ( acute ) , B C infection History hepatitis ( e.g. , alcohol nonalcohol steatohepatitis ( NASH ) , drugrelated , autoimmune ) Evidence active infection , require parenteral antibacterial , antiviral antifungal therapy &lt; 7 day prior administration study medication History clinically significant cardiac disease , include limited history ( personal family ) congenital long QT syndrome Grade &gt; 1 QTc prolongation baseline ( &gt; 450 msec Bazett formula ) confirm repeat electrocardiogram ( ECG ) History myocardial infarction uncontrolled angina within 12 month prior administration study drug 3 . Physical Laboratory Test Findings WOCBP unwilling unable use acceptable method avoid pregnancy entire study period 12 week last dose investigational product Women pregnant breastfeed Women positive pregnancy test enrollment prior investigational product administration Sexually active fertile men use effective birth control partner WOCBP Positive blood screen hepatitis A IgM , hepatitis C antibody , hepatitis B surface antigen , HIV1 , 2 antibody 4 . Allergies Adverse Drug Reaction History allergy Urelumab ( BMS663513 ) relate compound History significant drug allergy ( anaphylaxis hepatotoxicity ) prior biologic therapy 5 . Prohibited Treatments and/or Therapies The systemic use follow therapy prohibit within 28 day first dose study medication , longer indicate : 1 . Use anticancer treatment ( include investigational drug ) within 28 day 2 . Immunosuppressive medication immunosuppressive dos systemic corticosteroid 3 . Surgery ( except minor surgery , e.g. , biopsy ) radiotherapy 4 . Any nononcology live viral vaccine therapy use prevention infectious disease . Prior treatment antiprogrammed death 1 ( antiPD1 ) /Programmed cell death 1 ligand 1 ( PDL1 ) antiCD137 Any subject follow report drugrelated adverse event anti Cytotoxic TLymphocyte Antigen 4 ( antiCTLA4 ) permit study : hepatic , diarrhea/colitis endocrine adverse event ( AE ) Grade ≥ 2 , nonlaboratory immunerelated AE ≥ Grade 3 . Subjects must minimum 9 week washout period last dose antiCTLA4 first dose Urelumab ( BMS663513 ) Prior organ allograft allogeneic bone marrow transplantation 6 . Other Exclusion Criteria Prisoners subject involuntarily incarcerate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>